Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $64.75, but opened at $65.04. Ultragenyx Pharmaceutical shares last traded at $65.98, with a volume of 171,780 shares trading hands.

Several equities analysts recently commented on the company. Morgan Stanley reissued a “hold” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. JMP Securities reissued a “buy” rating and set a $84.00 price target (up from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. Jefferies Group reissued a “buy” rating and set a $109.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday, April 28th. Finally, Credit Suisse Group AG reissued a “buy” rating and set a $101.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 25th. Three equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $98.09.

The stock’s market capitalization is $2.51 billion. The firm’s 50 day moving average price is $54.51 and its 200 day moving average price is $61.78.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.29) by $0.06. During the same period in the prior year, the business earned ($0.63) earnings per share. Ultragenyx Pharmaceutical’s revenue was up .0% on a year-over-year basis. Analysts predict that Ultragenyx Pharmaceutical Inc. will post ($5.84) earnings per share for the current fiscal year.

In other news, insider Sunil Agarwal sold 650 shares of the company’s stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $66.00, for a total transaction of $42,900.00. Following the completion of the sale, the insider now owns 7,111 shares in the company, valued at approximately $469,326. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $50.85, for a total value of $1,017,000.00. Following the sale, the chief executive officer now owns 513,597 shares of the company’s stock, valued at approximately $26,116,407.45. The disclosure for this sale can be found here.

Other hedge funds recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Ultragenyx Pharmaceutical by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 2,393,587 shares of the biopharmaceutical company’s stock valued at $268,512,000 after buying an additional 275,497 shares during the period. Jennison Associates LLC increased its stake in Ultragenyx Pharmaceutical by 17.0% in the fourth quarter. Jennison Associates LLC now owns 755,388 shares of the biopharmaceutical company’s stock valued at $84,739,000 after buying an additional 109,724 shares during the period. Dimensional Fund Advisors LP increased its stake in Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock valued at $6,414,000 after buying an additional 5,139 shares during the period. New York State Common Retirement Fund increased its stake in Ultragenyx Pharmaceutical by 14.6% in the fourth quarter. New York State Common Retirement Fund now owns 56,877 shares of the biopharmaceutical company’s stock valued at $6,380,000 after buying an additional 7,240 shares during the period. Finally, California Public Employees Retirement System increased its stake in Ultragenyx Pharmaceutical by 7.6% in the fourth quarter. California Public Employees Retirement System now owns 55,300 shares of the biopharmaceutical company’s stock valued at $6,204,000 after buying an additional 3,900 shares during the period.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.